All In Biotech

BLA 761180 · Leo Pharma As

Adbry

Tralokinumab · Injection · Interleukin-13 Antagonist

Novel

CDER novel approval, Dec 27, 2021: To treat moderate-to-severe atopic dermatitis

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 27, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

37

15 Phase 3, 5 recruiting

FAERS reports

6,706

923 serious, 90 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 17, 2025.

ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ADBRY is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ( 1 )

Mechanism: Tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2). IL-13 is a naturally occurring cytokine of the Type 2 immune response. Tralokinumab-ldrm inhibits the bioactivity of IL-13 by blocking IL-13 interaction with IL-13Rα1/IL-4Rα receptor complex. Tralokinumab-ldrm inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE.

Therapeutic areas: Immunology and inflammation · Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADBRY · TRALOKINUMAB 150MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tralokinumab" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dermatitis atopic900
  • drug ineffective856
  • pruritus735
  • rash496
  • eczema465
  • injection site pain432
  • dry skin287
  • injection site erythema239
  • erythema225
  • product use in unapproved indication223
  • injection site pruritus208
  • injection site swelling198

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20202
20211
2022549
20231,020
20241,641
20251,894
20261,599

Recalls

1 FDA enforcement reports for this application.

  • Feb 10, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adbry (Tralokinumab-Ldrm)

2024 spending

$49.5M

Beneficiaries

2,251

12,832 claims

Per beneficiary

$22,003

$939.80 per unit

View as table
YearSpending
2020$0
2021$0
2022$11,498,067
2023$31,579,580
2024$49,529,246

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 70 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.